Mohammad A Rafi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2382989/publications.pdf

Version: 2024-02-01

41 papers	1,992 citations	257101 24 h-index	288905 40 g-index
41 all docs	41 docs citations	41 times ranked	1771 citing authors

#	Article	IF	Citations
1	Molecular genetics of Krabbe disease (globoid cell leukodystrophy): Diagnostic and clinical implications. , 1997, 10, 268-279.		197
2	Blood-brain barrier transport machineries and targeted therapy of brain diseases. BioImpacts, 2016, 6, 225-248.	0.7	174
3	Cloning and expression cDNA encoding human galactocerebrosidase, the enzyme deficient in globoid cell leukodystrophy. Human Molecular Genetics, 1993, 2, 1841-1846.	1.4	145
4	Epitope-based vaccine design: a comprehensive overview of bioinformatics approaches. Drug Discovery Today, 2020, 25, 1034-1042.	3.2	120
5	A large deletion together with a point mutation in the GALC gene is a common mutant allele in patients with infantile Krabbe disease. Human Molecular Genetics, 1995, 4, 1285-1289.	1.4	108
6	AAV-Mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy. Molecular Therapy, 2005, 11, 734-744.	3.7	95
7	Extended Normal Life After AAVrh10-mediated Gene Therapy in the Mouse Model of Krabbe Disease. Molecular Therapy, 2012, 20, 2031-2042.	3.7	93
8	AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2. Molecular Therapy, 2005, 12, 422-430.	3.7	89
9	Structure and organization of the human galactocerebrosidase (GALC) gene. Genomics, 1995, 26, 407-409.	1.3	86
10	Characterization of the large deletion in the GALC gene found in patients with Krabbe disease. Human Molecular Genetics, 1995, 4, 2335-2338.	1.4	75
11	Two different mutations are responsible for Krabbe disease in the Druze and Moslem Arab populations in Israel. Human Genetics, 1996, 97, 304-308.	1.8	64
12	Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy. Brain Research, 2009, 1300, 146-158.	1.1	64
13	Multiple mutations in the GALC gene in a patient with adult-onset krabbe disease. Annals of Neurology, 1996, 40, 116-119.	2.8	58
14	Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher Mice. Molecular Therapy, 2015, 23, 1681-1690.	3.7	52
15	Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors. Expert Opinion on Drug Delivery, 2019, 16, 583-605.	2.4	45
16	Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features. Molecular Genetics and Metabolism, 2015, 114, 459-466.	0.5	43
17	Enzyme replacement therapies: what is the best option?. BioImpacts, 2018, 8, 153-157.	0.7	41
18	Retroviral Vector-Mediated Transfer of the Galactocerebrosidase (GALC) cDNA Leads to Overexpression and Transfer of GALC Activity to Neighboring Cells. Biochemical and Molecular Medicine, 1996, 58, 142-150.	1.5	40

#	Article	IF	Citations
19	Disease-causing mutations in cis with the common arylsulfatase A pseudodeficiency allele compound the difficulties in accurately identifying patients and carriers of metachromatic leukodystrophy. Molecular Genetics and Metabolism, 2003, 79, 83-90.	0.5	40
20	Significant correction of pathology in brains of twitcher mice following injection of genetically modified mouse neural progenitor cells. Molecular Genetics and Metabolism, 2009, 97, 27-34.	0.5	40
21	Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke. Journal of Drug Targeting, 2018, 26, 95-109.	2.1	35
22	Krabbe disease: Are certain mutations disease-causing only when specific polymorphisms are present or when inherited in trans with specific second mutations?. Molecular Genetics and Metabolism, 2014, 111, 307-308.	0.5	34
23	<scp>K</scp>rabbe disease: One Hundred years from the bedside to the bench to the bedside. Journal of Neuroscience Research, 2016, 94, 982-989.	1.3	31
24	Biochemical and pathological evaluation of long-lived mice with globoid cell leukodystrophy after bone marrow transplantation. Molecular Genetics and Metabolism, 2005, 86, 150-159.	0.5	29
25	Transduction of cultured oligodendrocytes from normal and twitcher mice by a retroviral vector containing human galactocerebrosidase (GALC) cDNA. Neurochemical Research, 1999, 24, 287-293.	1.6	24
26	Bioengineered smart bacterial carriers for combinational targeted therapy of solid tumours. Journal of Drug Targeting, 2020, 28, 700-713.	2.1	24
27	Conditions for combining gene therapy with bone marrow transplantation in murine Krabbe disease. BioImpacts, 2020, 10, 105-115.	0.7	18
28	Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis. Cellular and Molecular Life Sciences, 2019, 76, 3363-3381.	2.4	16
29	A prospective highlight on exosomal nanoshuttles and cancer immunotherapy and vaccination. BioImpacts, 2015, 5, 117-122.	0.7	16
30	Gene and stem cell therapy: alone or in combination?. BioImpacts, 2011, 1, 213-8.	0.7	16
31	To impact or not to impact, this is not a question for BioImpacts!. BioImpacts, 2015, 5, 1-2.	0.7	13
32	Debate on human aging and lifespan. BioImpacts, 2017, 7, 135-137.	0.7	12
33	Mathematical Models to Shed Light on Amyloid-Beta and Tau Protein Dependent Pathologies in Alzheimerâ€™s Disease. Neuroscience, 2020, 424, 45-57.	1.1	10
34	Can early treatment of twitcher mice with high dose AAVrh10-GALC eliminate the need for BMT?. BioImpacts, 2021, 11, 135-146.	0.7	10
35	Advances in the Diagnosis and Treatment of Krabbe Disease. International Journal of Neonatal Screening, 2021, 7, 57.	1.2	9
36	Lysosomal storage diseases: heterogeneous group of disorders. BioImpacts, 2013, 3, 145-7.	0.7	9

#	Article	IF	Citations
37	Spectrophotometric analysis of thrombolytic activity: SATA assay. BioImpacts, 2018, 8, 31-38.	0.7	8
38	Gene therapy for CNS diseases â€“ Krabbe disease. BioImpacts, 2016, 6, 69-70.	0.7	4
39	Enzyme replacement combinational therapy: effective treatments for mucopolysaccharidoses. Expert Opinion on Biological Therapy, 2021, 21, 1181-1197.	1.4	3
40	BioImpacts: An emerging global journal. BioImpacts, 2020, 10, 207-208.	0.7	1
41	Krabbe disease: A personal perspective and hypothesis.. BioImpacts, 2022, 12, 3-7.	0.7	1